Lv61
2700 积分 2022-08-08 加入
Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial
1小时前
已完结
Predictive factors of atopic‐like dermatitis induced by IL‐17A inhibitors in patients with psoriasis: A 2‐year follow‐up study
11天前
已完结
原发性慢性青光眼患者双眼视觉和生活质量相关性研究
1个月前
已完结
An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA
1个月前
已完结
Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy
1个月前
已完结
Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody that targets interleukin-17A, in healthy participants and patients with moderate-to-severe plaque psoriasis
2个月前
已完结
How we prevent infections in adults receiving bispecific antibody therapies for advanced B-cell malignancies
2个月前
已关闭
A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis
2个月前
已完结
Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1)
2个月前
已完结
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
